Hope third time is a charm for him and us. $heff was long on MEIP when it crashed in March and took a bath, then he took a position again at about $2.06 a few months ago then sold off. 3rd times is a charm I hope
Lets see here, MEIP data in AML patients is looking so thus far, data in MDS patients is almost doubling disease free survival (in patients who did not drop out). If all this does not warrant phase 3 with pracinostat then I am not sure what on earth will take to get a drug to phase 3.
I doubt we see much activity till Oct /Nov, hopefully then it might run up to ASH and get o break $2 . All upstrokes since March have been beaten down
God, this got whipped today. Hate to think what might have happened but for the good data last week, Now just hope the data continues to be good till ASD Dec 5, any less than good news for a biotech in this market could be devastating.
Hopefully we can get get to $4- $5 soon where it belongs. ASH abstracts online will MDS and AML data so far on Nov 5, that is10 weeks away, hopefully we have a run up.
If we had the same data in March with Pracinostat that we are getting now, this stock would have been very likely in $6-$10 range, considering it was trading at $6.50 before the March crash when interim MDS data results were disclosed.
Full Article posted on Investorshub MEIP board today
Like to see higher volume, but so far it continues to move up I am ok with it. Refractory MDS data is expected this month. Hope we get something there, though I expect front line MDS due in Dec ASH to be better.
The stock ran up to $6.50 before interim data in March, then crashed on poor MDS data . Now we know that the MDS data is turning out to be good and AML data continues to impress. If the trend continues, I see no reason why the stock should not be at least 2-3 times from her by Dec
As per Dr. Gold MDS patients who were able to withstand more than 4 cycles of Vidaza + Pracinostat for MDS had an almost double relapse free survival so far. The failure of the March interim data was skewed on account of high drop out of 25% which was not seen in AML study. As AML patients are sicker, they were convinced to stay of treatment longer, the drop out was much less as they were convinced to stay on treatment despite fatigue, diarrhea etc. The response to Pracinostat can be in just 1-2 cycles but for complete remission take more cycles, so patients have to be convinced to stay on treatment longer. So far AML data patients looks very good with Vidaza/Prancinostat combo - Complete response in 42 % vs 20% on Vidaza alone, 60 day mortality is 1/2 with combination, 60% 1 year survival vs 46% Vidaza.
In addition to this ME 344 and PWT 143 is looking good so far. Looks good going forward, this should run up
62 % AML patients are still alive, as the last patient in phase AM phase 2 trial were enrolled in Nov 2014, Dr. Gold said they wanted to wait till Nov to get the full 1 year data in all patients, but as mentioned above results are optimistic thus far. The company want as much info they can get from their AML and MDS patients, all of which which will be available and presented Dec 5-8 ASH. They want all the info before starting phase 3. The full data will enable them to formulate phase 3 trial with greatest chance of success - The optimum dosage for phase 3 patients, select patients who are most likely to respond and tolerate the 2 drugs regimen of Pracinostat and Vidaza etc. The good part is the benefit in MDS patients, the interim data in March looked bad because of discontinuations, but in patients continuing treatment are showing benefit. Dec 5-8 ASH is the biggest catalyst for meip thus far with data from other 2 drugs PWT 143 and . ME 344 data as well. Meip runs up every 6 months, I expect it to run up to $3-$4 by Nov end.
62% patients of AML on Pracinostat are still alive. The ASH meeting Dec 5-8 will have full data for AML,MDS in addition PWT 143 data will be presented at ASH too. ME 344 data expected around at that time too. So ASH going to be the biggest catalyst so far for the company. Meip runs up every 6 months for the past about 6 times, expect run up to take it to $3-$4 range by Nov.
Per Frigate Ventures Lp’s filing, the filler now owns 5% of the company, holding 1,715,000 shares.
Mei Pharma, Inc is a newly disclosed equity position for this institutional investor and the filing was required due to activity on July28, 2015. This most probably shows Frigate Ventures Lp’s confidence and optimism in the future of the company. As a institutional investor with $326.98 million AUM and 5+ professional employees, we have no reason to doubt they didn’t do their homework before buying such a stake.
Can be gooled for more info
Reveal more than 5%, 1,715,000 share ownership in today's filing. New investors, no record of them being prior investors. Explains the pop on Friday, I suppose.
That is true, float is small. They need to announce phase 3 with Pracinostat which they should, that alone should propel the stock to $6-$8 before phase 3 results. If ME-344 shows good results and they move that to further trials, that will be additional positive. Lot of data should be coming out in next few months.